Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI

Clinical and Experimental Metastasis

Volumn 29, Issue 1, 2012, Pages 51-62

  Budde, Matthew D ^a   Gold, Eric ^a   Jordan, E Kay ^a   Frank, Joseph A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Apparent diffusion coefficient; Biomarker; Brain metastasis; Breast cancer; Dynamic contrast enhancement; Magnetic resonance imaging; Vessel co option

Indexed keywords

GADOLINIUM PENTETATE; CONTRAST MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER MODEL; CELL STRUCTURE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; RAT; ANIMAL; BONE TUMOR; BRAIN TUMOR; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; METASTASIS; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; RATS;

EID: 84856015107     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9428-2     Document Type: Article

References (56)

1. Tkaczuk KH (2009) Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 31(Pt 2):2273-2289
2. Gril B et al (2010) Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 46(7):1204-1210
3. Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract 5(4):206-219 (Pubitemid 351493680)
4. Weil RJ et al (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167(4):913-920 (Pubitemid 41416243)
5. Nicolson GL (1988) Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7(2):143-188
6. Palmieri D et al (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13(6):1656-1662 (Pubitemid 46957363)
7. Carbonell WS et al (2009) The vascular basement membrane as "soil" in brain metastasis. PLoS One 4(6):e5857
8. Kienast Y et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16(1):116-122
9. Lockman PR et al (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16(23):5664-5678
10. Thomas FC et al (2009) Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 26(11): 2486-2494
11. Leenders WP et al (2004) Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10(18 Pt 1):6222-6230 (Pubitemid 39287530)
12. Lin NU et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12):1993-1999
13. Luu TH et al (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14(21):7138-7142
14. Trudeau ME et al (2006) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17(6): 952-956 (Pubitemid 43778985)
15. Morris PG, McArthur HL, Hudis CA (2009) Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 10(6): 967-981
16. Marty M, Pivot X (2008) The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 44(7):912-920
17. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
18. Moffat BA et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102(15):5524-5529 (Pubitemid 40530291)
19. Moffat BA et al (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8(4):259-267
20. Barrett T et al (2007) MRI of tumor angiogenesis. J Magn Reson Imaging 26(2):235-249 (Pubitemid 47257720)
21. Sargent DJ et al (2009) Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 45(2):290-299
22. Song HT et al (2009) Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med 7:88
23. Hasan KM, Parker DL, Alexander AL (2001) Comparison of gradient encoding schemes for diffusion-tensor MRI. J Magn Reson Imaging 13(5):769-780 (Pubitemid 32381856)
24. Wang HZ, Riederer SJ, Lee JN (1987) Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn Reson Med 5(5):399-416 (Pubitemid 17167630)
25. Yankeelov TE, Gore JC (2009) Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 3(2):91-107 (Pubitemid 46773870)
26. Parker GJ et al (1997) Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7(3):564-574 (Pubitemid 28360876)
27. Noebauer-Huhmann IM et al (2010) Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. Invest Radiol 45(9):554-558
28. Woods RP et al (1998) Automated image registration: II. Intersubject validation of linear and nonlinear models. J Comput Assist Tomogr 22(1):153-165 (Pubitemid 28087338)
29. Hawkins BT, Egleton RD (2006) Fluorescence imaging of blood-brain barrier disruption. J Neurosci Methods 151(2):262-267 (Pubitemid 43294448)
30. Bauerle T et al (2010) Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res 16(12):3215-3225
31. Bauerle T et al (2010) Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol 73(2): 280-287
32. Lee KC et al (2007) An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67(8):3524-3528 (Pubitemid 46762131)
33. Lee KC et al (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9(12):1003-1011 (Pubitemid 350255347)
34. Blasberg RG et al (1984) Local blood-to-tissue transport in Walker 256 metastatic brain tumors. J Neurooncol 2(3):205-218 (Pubitemid 14046710)
35. Zhang RD et al (1992) Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141(5):1115-1124
36. Duygulu G et al (2010) Intracerebral metastasis showing restricted diffusion: correlation with histopathologic findings. Eur J Radiol 74(1):117-120
37. Krabbe K et al (1997) MR diffusion imaging of human intracranial tumours. Neuroradiology 39(7):483-489 (Pubitemid 27298110)
38. Yoneda T et al (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16(8):1486-1495 (Pubitemid 32675200)
39. Song HT et al. (2010) Quantitative T(2)* imaging of metastatic human breast cancer to brain in the nude rat at 3 T. NMR Biomed 24:325-334
40. Palmieri D et al (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67(9):4190-4198 (Pubitemid 46815065)
41. Charles N, Holland EC (2010) The perivascular niche microenvironment in brain tumor progression. Cell Cycle 9(15): 3012-3021
42. Fitzgerald DP et al (2008) Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 25(7):799-810
43. Park JS, Bateman MC, Goldberg MP (1996) Rapid alterations in dendrite morphology during sublethal hypoxia or glutamate receptor activation. Neurobiol Dis 3(3):215-227 (Pubitemid 26391325)
44. Rzeski W, Turski L, Ikonomidou C (2001) Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98(11):6372-6377 (Pubitemid 32488244)
45. Takano T et al (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7(9):1010-1015 (Pubitemid 32937380)
46. Seidlitz EP et al (2009) Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis 26(7): 781-787
47. Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383-4391 (Pubitemid 29418758)
48. Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84(4):397-405 (Pubitemid 41656467)
49. Dome B et al (2007) Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170(1):1-15 (Pubitemid 47339184)
50. Indelicato M et al (2010) Role of hypoxia and autophagy in MDA-MB-231 invasiveness. J Cell Physiol 223(2):359-368
51. Hayashida Y et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27(7):1419-1425 (Pubitemid 44260120)
52. Sugahara T et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9(1):53-60 (Pubitemid 29068231)
53. Prasad SR et al (2003) Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr 27(3):380-384 (Pubitemid 36793188)
54. Shelton LM et al (2010) A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol 99(2):165-176
55. Heyn C et al (2006) In vivo MRI of cancer cell fate at the singlecell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 56(5):1001-1010 (Pubitemid 44691342)
56. Leenders W et al (2003) Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int J Cancer 105(4): 437-443 (Pubitemid 36578545)